(Q34601249)

3 August 2017

title

Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia (English)

1 reference

3 August 2017

1 reference

7

Hagop Kantarjian

1 reference

3 August 2017

6

Jorge Cortes

1 reference

3 August 2017

3

Farhad Ravandi

1 reference

3 August 2017

2

Gautam Borthakur

1 reference

3 August 2017

4

Jianqin Shan

1 reference

3 August 2017

1

Ahmed Aribi

1 reference

3 August 2017

5

Jan Davisson

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 February 2007

1 reference

3 August 2017

1 reference

3 August 2017

volume

109

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

713-717

1 reference

Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22457

7 January 2021

Identifiers

DOI

10.1002/CNCR.22457

1 reference

3 August 2017

1 reference